Sanofi has asked the U.S. Food and Drug Administration to pull its diabetes drug out of the regulator's new fast-track review ...

Sanofi has asked the FDA to pull its type 1 diabetes drug out of Commissioner Marty Makary’s new speedy drug review program.

U.S. President Donald Trump announced on Friday that the federal government is taking steps to expand access to GLP-1 ...

Ozempic is now available in pill form for people with type 2 diabetes. Novo Nordisk says the oral GLP-1's new lower-dose ...

Add Yahoo as a preferred source to see more of our stories on Google. According to the WHO, more than 800 million people around the world have diabetes, with more than half of them not receiving ...

People taking GLP-1 drugs had a 14% lower risk of experiencing a major heart event compared to those on a placebo. The benefits extended across the board: fewer deaths overall, fewer non-fatal heart ...

Whether you have type 2 diabetes, obesity or just a few extra pounds that you’d like some help shedding, chances are you’re one of the millions of adults worldwide who heard about Novo Nordisk’s ...

Drugs developed for the treatment of type 2 diabetes or obesity-related conditions have stood out due to their weight-loss ...

A new study, published in JAMA Neurology, finds that people with type 2 diabetes who take two common anti-diabetes medications had a reduced risk of Alzheimer’s and associated dementias. Specifically, ...

Maryland’s Prescription Drug Affordability Board voted Monday to restrict the price that state and local employees will have to pay for two medicines for type 2 diabetes, Jaridance and Farxiga. The ...

Every year, millions of Indians managing diabetes diligently track their blood sugar, watch their diet, and take their ...

Diabetes is a common, chronic (lifelong) condition affecting people of all ages. According to the Centers for Disease Control ...